Fulcrum Therapeutics (FULC) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Fulcrum Expands GIS Integration With Full Support for Esri ArcGIS Enterprise Deployments
PR NewswireOct 16 10:00 ET
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
Yahoo FinanceOct 7 15:02 ET
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
Zacks Oct 4 08:40 ET
Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity
WSJSep 26 12:41 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
BenzingaSep 26 12:31 ET
Fulcrum Therapeutics Potential Winner After Pfizer Pulls Oxbryta -- Market Talk
WSJSep 26 12:17 ET

Comments

Bigmoney Dreamer

Sep 26 19:48

$Fulcrum Therapeutics (FULC.US)$ 👀lot of meat on forcast but pattern is behaving like walking drunk man….

1

Jaguar8

Sep 12 07:11

NEWS

$Fulcrum Therapeutics (FULC.US)$
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...

Trytosaveabit

Jul 31 12:53

Up is the way!

$Fulcrum Therapeutics (FULC.US)$ Low volume indeed! But low or high volume, all that matters is that it’s moving up nicely

1

Trytosaveabit

Jul 31 06:11

Talk about a under estimated or a killer unexpected operating income! Hehehe!

$Fulcrum Therapeutics (FULC.US)$ Fulcrum Therapeutics Q2 Operating Income USD 52.492 Million Vs. IBES Estimate USD 361.4 Thousand! Hope the rest of the earnings looks like this? hehehe

2

12

Trytosaveabit

May 23 08:23

Note the timeline

$Fulcrum Therapeutics (FULC.US)$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.

1

2

FULC Fulcrum Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target